NL-1

Modify Date: 2025-08-25 17:59:12

NL-1 Structure
NL-1 structure
Common Name NL-1
CAS Number 188532-26-5 Molecular Weight 335.46100
Density N/A Boiling Point N/A
Molecular Formula C18H25NO3S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of NL-1


NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway[1].

 Names

Name NL-1

 NL-1 Biological Activity

Description NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway[1].
Related Catalog
Target

MitoNEET[1]

In Vitro NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 µM for NL-1[1]. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death[1]. NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells[1]. Cell Proliferation Assay[1] Cell Line: REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines Concentration: 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM Incubation Time: 72 hours Result: Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. Cell Autophagy Assay[1] Cell Line: REH, REH/Ara-C cell lines Concentration: 60 μM Incubation Time: 6 hours Result: Induced cell autophagy.
In Vivo NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model[1]. Animal Model: 10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; daily; for 5 days Result: Showed antileukemic activity in an in vivo mouse ALL model.
References

[1]. Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.

 Chemical & Physical Properties

Molecular Formula C18H25NO3S
Molecular Weight 335.46100
Exact Mass 335.15600
PSA 91.70000
LogP 4.21010

 Safety Information

Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here



Get all suppliers and price by the below link:

NL-1 suppliers

NL-1 price